Literature DB >> 11162808

Mucosal exposure to subinfectious doses of SIV primes gut-associated antibody-secreting cells and T cells: lack of enhancement by nonneutralizing antibody.

N Polyanskaya1, L A Bergmeier, S A Sharpe, N Cook, S Leech, G Hall, M Dennis, P ten Haaft, J Heeney, F Manca, T Lehner, M P Cranage.   

Abstract

It has been suggested that the presence of immunoglobulin and complement receptors on rectal epithelium may facilitate the entry of HIV complexed to nonneutralizing antibody. We tested this hypothesis using simian immunodeficiency virus (SIV) infection of rhesus macaques. First, in a pilot study, a nonneutralizing IgG fraction of macaque anti-SIV gp120 was shown to enhance the immunogenicity of SIV envelope following rectal immunization. The same antibody was then mixed with a subinfectious dose of SIV and the occurrence of rectal infection was compared with virus alone. Animals were not infected overtly and were rechallenged with a 10-fold higher dose of virus with and without addition of antibody. There was no evidence of antibody-mediated infection, since equal numbers of macaques became infected, regardless of the presence of antibody. In addition, the application of immune complexes did not alter significantly the subsequent virus load or the immune responses generated. In seronegative animals, in which virus and proviral DNA were undetectable in PBMC and tissues, SIV-specific T-cell responses and antibody-secreting cells were found in systemic and gut-associated sites. Our results show that nonneutralizing antibody neither facilitated nor enhanced rectal infection with SIV, in the small number of animals used, despite the consistent trend for this antibody to enhance antibody responses to gp120 following rectal immunization with immune-complexed antigen. However, mucosal exposure to subinfectious doses of virus primed both systemic and local immunity, regardless of addition of nonneutralizing antibody.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11162808     DOI: 10.1006/viro.2000.0704

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  6 in total

Review 1.  Molecular Pharming: future targets and aspirations.

Authors:  Mathew Paul; Craig van Dolleweerd; Pascal M W Drake; Rajko Reljic; Harry Thangaraj; Tommaso Barbi; Elena Stylianou; Ilaria Pepponi; Leonard Both; Verena Hehle; Luisa Madeira; Varghese Inchakalody; Sammy Ho; Thais Guerra; Julian K-C Ma
Journal:  Hum Vaccin       Date:  2011-03-01

Review 2.  AIDS vaccines and preexposure prophylaxis: is synergy possible?

Authors:  Jean-Louis Excler; Wasima Rida; Frances Priddy; Jill Gilmour; Adrian B McDermott; Anatoli Kamali; Omu Anzala; Gaudensia Mutua; Eduard J Sanders; Wayne Koff; Seth Berkley; Patricia Fast
Journal:  AIDS Res Hum Retroviruses       Date:  2010-12-16       Impact factor: 2.205

3.  Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.

Authors:  Martin P Cranage; Carol A Fraser; Alethea Cope; Paul F McKay; Michael S Seaman; Tom Cole; A Nasir Mahmoud; Joanna Hall; Elaine Giles; Gerald Voss; Mark Page; Neil Almond; Robin J Shattock
Journal:  Vaccine       Date:  2010-12-25       Impact factor: 3.641

4.  Immune-complex mimics as a molecular platform for adjuvant-free vaccine delivery.

Authors:  Ilaria Pepponi; Elena Stylianou; Craig van Dolleweerd; Gil Reynolds Diogo; Matthew J Paul; Pascal M W Drake; Julian K-C Ma; Rajko Reljic
Journal:  PLoS One       Date:  2013-04-23       Impact factor: 3.240

5.  Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel.

Authors:  Martin Cranage; Sally Sharpe; Carolina Herrera; Alethea Cope; Mike Dennis; Neil Berry; Claire Ham; Jonathan Heeney; Naser Rezk; Angela Kashuba; Peter Anton; Ian McGowan; Robin Shattock
Journal:  PLoS Med       Date:  2008-08-05       Impact factor: 11.069

Review 6.  Immunoregulatory functions of immune complexes in vaccine and therapy.

Authors:  Yu-Mei Wen; Libing Mu; Yan Shi
Journal:  EMBO Mol Med       Date:  2016-10-04       Impact factor: 12.137

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.